Cellular Signal Transduction Pathways for Anesthetic-induced Cardioprotection

Login or register to view PDF.

Cardiovascular disease is a major healthcare problem in the US. The presence of this disease significantly affects the outcome of both cardiac and non-cardiac surgery, and peri-operative cardiac morbidity is one of the leading causes of death following anesthesia and surgery. The considerable incidence of myocardial infarction, congestive heart failure, myocardial ischemia, or serious dysrhythmias during the intra-operative or post-operative periods has led many studies to examine medical factors and interventions for decreasing cardiac risk in patients with cardiovascular disease. An extensive amount of work has focused on whether any one anesthetic agent or technique is particularly beneficial for patients with coronary artery disease (CAD). Experimental studies conducted in the laboratory have clearly demonstrated that volatile anesthetics exert profound cardioprotection against myocardial ischemia and reperfusion injury. The purpose of this overview is to summarize the interaction of volatile anesthetics with ischemic myocardium and briefly discuss the underlying mechanisms of cardioprotection against ischemia and reperfusion injury.

Discussion

Myocardium is sensitive to hypoxia and ischemia, which can lead to extensive and irreversible tissue injury. However, short periods of ischemia, called ischemic pre-conditioning (IPC), prior to a prolonged ischemic insult, can reduce the severity of cardiac injury. IPC has been studied extensively for the past 20 years and has resulted in the publication of more than 2,000 articles, which have significantly increased our understanding of the cellular mechanisms of ischemia and reperfusion injury. IPC was initially described in 19861 by Murray et al., who demonstrated that four five-minute periods of coronary artery occlusion interspersed with five-minute periods of reperfusion before a prolonged coronary occlusion produced a reduction in myocardial infarct size in dogs. Pre-conditioning can also be induced in humans undergoing percutaneous transluminal coronary angioplasty with a coronary occlusion of two minutesÔÇÖ duration.2

Certain pharmacological agents can mimic IPC. Experimental and clinical data indicate that volatile anesthetics may pre-condition the myocardium against ischemia and infarction by activating endogenous protective cellular mechanisms. This is anesthetic-induced pre-conditioning (APC).3 Myocardial protection by volatile anesthetics is of clinical relevance for patients with CAD because of their high morbidity and because of their mortality, which is secondary to peri-operative myocardial ischemia. The beneficial effects of APC in patients have also been reported.4-10

The mechanisms by which volatile anesthetics exert protective actions on ischemic myocardium have previously been attributed to an improvement in the relationship between myocardial oxygen supply and demand. For example, our research has reported that volatile anesthetics are negative inotropes that decrease left ventricular contractility and depress sino-atrial nodal function. These actions decrease myocardial oxygen demand.11,12 Although a portion of the cardioprotective effects of volatile anesthetics following ischemia and reperfusion may be attributed to a reduction in energy requirements and the ultimate preservation of energy-dependent vital cellular processes, other studies have demonstrated that this is not necessary for cardioprotection. For example, volatile anesthetics exert cardioprotective effects even when administered during cardioplegic arrest and at reperfusion. Many components of the signaling pathway leading to cardioprotection are shared by IPC and APC. Laboratory and other studies have identified a signaling cascade, as shown in Figure 1, that involves reactive oxygen species (ROS), G-protein-coupled receptors, protein kinases, and adenosine triphosphate (ATP)-sensitive potassium channels.3,13-40

APC is as powerful as IPC in reducing infarct size, and ATP-sensitive potassium (KATP) channels have long been considered essential components of this process. There are two types of KATP channels in cardiac myocytesÔÇömitochondrial (mitoKATP) channels, which are located in the inner mitochondrial membrane, and sarcolemmal (sarcKATP) channels, which are located in the plasma membrane. After the discovery of the mitoKATP channels in the inner mitochondrial membrane and development of selective mitoKATP and sarcKATP channel inhibitors, evidence suggested that mitoKATP channels may play a more important role in cardioprotection than sarcKATP channels. Some of the recent studies that involved the use of sarcKATP-specific inhibitors and genetic models of disrupted or knocked-out sarcKATP-channel sub-units indicate that sarcKATP channels may have a role in cardioprotection and should not be ignored.41,42

Our research utilized patch clamp methodology to directly demonstrate that isoflurane can stimulate KATP channels in isolated ventricular myocytes.13,31,32,38,39,43,44 In addition, it was demonstrated that the KATP channel agonist pinacidil exerts greater effects to open the KATP channel in myocytes that were previously exposed to isoflurane. Isoflurane may diminish the sensitivity of the KATP channels to inhibition by ATP and therefore increase the probability of this channel being in the open state.44

Recent findings suggest that an opening of the mitoKATP channels is critically involved in IPC and induces reversible oxidation of the mitochondrial matrix.45-48 Opening of mitoKATP channels can dissipate the inner mitochondrial membrane potential established by the proton pump. The effects of anesthetics on mitochondrial redox state were examined by recording the fluorescence of FAD-linked enzymes. The results indicate that isoflurane and sevoflurane dose-dependently increase flavoprotein fluorescence.22,26,49,50 Additional studies are being conducted to examine human cardiac KATP channels using the artificial lipid bilayer.51

The role of A1-receptor stimulation in the enhancement of recovery of contractile function of stunned myocardium by isoflurane was also examined.52 These and other studies suggest that isoflurane either directly activates A1 receptors or indirectly enhances the sensitivity of A1-receptors to reduced amounts of endogenously released adenosine.53 This protection could be reversed by adenosine receptor antagonists, Gi protein blockers, protein kinase C (PKC) inhibitors, and KATP channel blockers. Therefore, it may be hypothesised that inhalational anesthetics could stimulate these receptors, proteins, and signal transduction pathways, including the KATP channels. As research has demonstrated that cardioprotection by anesthetics is not accompanied by augmented release of adenosine, it could be postulated that these receptors, signal transduction pathways, and KATP channels may be sensitised to protein/channel modulators.

Recent studies indicate that both the sarcKATP and the mitoKATP channels are essential for the protection of myocytes from damage by oxidative stress since their inhibition completely abolished the protective effects of pre-conditioning by isoflurane. Specifically, activation of the sarcKATP channel was required for the cardioprotective effects of APC during the stress period, but not during the pre-conditioning period. In contrast, activation of the mitoKATP channel was found to be necessary for protection during both isoflurane pre-conditioning and exposure to oxidative stress. From these results, it appears that although activation of both channels is important for the cardioprotective effects of APC, each channel performs a distinct roleÔÇöthe sarcKATP channel acts as an effector, while the mitoKATP channel plays a dual role as a trigger and an effector.

The role of the mitoKATP channel as both a trigger and an effector, and the sarcKATP channel as the effector of APC, could be explained by the following sequence of events.

  • Exposure to isoflurane can directly activate mitoKATP channels, resulting in changes in mitochondrial bioenergetics producing a small burst of ROS.54
  • The ROS can activate cytosolic mediators such as PKC that translocate to the sarcolemma, phosphorylate the sarcKATP channel, and sensitize it to opening.
  • The newly primed sarcKATP channel opens sooner during subsequent metabolic stress, resulting in a greater K+ efflux, a more rapid re-polarization of the cell membrane, and action potential shortening, which leads to a decrease in cytosolic Ca2+ loading during ischemia/reperfusion. This can reduce or prevent mitochondrial Ca2+ overload, a major trigger of the cell death pathway.
  • The mitoKATP channel can also open during ischemia/reperfusion, which may result in the depolarization of the inner mitochondrial membrane and thus further decrease a driving force for mitochondrial Ca2+ entry and accumulation during ischemia/reperfusion.

Modulation of the KATP channels by pharmacological agonists and antagonists may produce additional direct cardiac effects. For example, in response to the KATP agonist-induced shortening of action potential duration, a concomitant reduction in calcium influx was associated with prevention of triggered arrhythmias.55,56 However, KATP channel agonists also appear to exacerbate re-entry arrhythmias. Glyburide prevents action-potential shortening and may suppress re-entrant arrhythmias. It may also lead to increased triggered activity.57,58 Therefore, modulation of the KATP channels with pharmacological agonists and antagonists may produce either detrimental or beneficial effects on cardiac electrophysiology.59 Nevertheless, in addition to the KATP channel modulation, volatile anesthetic actions that involve changes in the intracellular regulation of other major trans-sarcolemmal ionic channels can play a critical role in the protection against ischemia and reperfusion arrhythmogenesis.

Conclusion

The observation that volatile anesthetics protect ischemic myocardium is important and clinically significant for patients with CAD. Their morbidity and mortality that is secondary to peri-operative myocardial ischemia is disproportionately high. Current data indicate that APC occurs, and myocardium can be rendered resistant to ischemia and reperfusion injury for a prolonged period, after a prior, brief exposure to a volatile anesthetic. APC displays many similarities to IPC including a window of protection that has also been confirmed in patients undergoing coronary bypass graft and other surgeries. Ôûá

References
  1. Murry CE, Jennings RB, Reimer KA, Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium , Circulation (1986); 74: pp. 1124-36.
    Crossref | PubMed
  2. Deutsch E, Berger M, Kussmaul WG, et al., Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features , Circulation (1990); 82: pp. 2044-51.
    Crossref | PubMed
  3. Kersten JR, Schmeling TJ, Pagel PS, et al., Isoflurane mimics ischemic preconditioning via activation of KATP channels: Reduction of myocardial infarct size with an acute memory phase , Anesthesiology (1997); 87: pp. 361-70.
    Crossref | PubMed
  4. Belhomme D, Peynet J, Louzy M, et al., Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery , Circulation (1999); 100: pp. II340-44.
    Crossref | PubMed
  5. De Hert SG,Van der Linden PJ, Cromheecke S, et al., Choice of primary anaesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass Anesthesiology (2004); 101: pp. 9-20.
    Crossref | PubMed
  6. De Hert SG,Van der Linden PJ, Cromheecke S, et al., Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration , Anesthesiology (2004); 101: pp. 299-310.
    Crossref | PubMed
  7. Julier K, da Silva R, Garcia C, et al., Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study , Anesthesiology (2003); 98: pp. 1315-27.
    Crossref | PubMed
  8. Zaugg M, Lucchinetti E, Garcia C, et al., Anaesthetics and cardiac preconditioning. Part II. Clinical implications , Br J Anaesth (2003); 91: pp. 566-76.
    Crossref | PubMed
  9. Zaugg M, Lucchinetti E, Uecker M, et al., Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms , Br J Anaesth (2003); 91: pp. 551-65.
    Crossref | PubMed
  10. Tomai F, Crea F, Ghini AS, et al., Ischemic preconditioning during coronary angioplasty is preserved in elderly patients [In Process Citation] , Ital Heart J (2000); 1: pp. 562-8.
    PubMed
  11. Bosnjak ZJ,Warltier DC, New aspects of cardiac electrophysiology and function: Effects of inhalational anesthetics , Vol. 7. Inhalation Anaesthesia, Bailliere Tindall Ltd (1993); 7: pp. 937-60.
    Crossref
  12. Buljubasic N, Stowe DF, Marijic J, et al., Halothane reduces release of adenosine, inosine, and lactate with ischemia and reperfusion in isolated hearts , Anesth Analg (1993); 76: pp. 54-62.
    Crossref | PubMed
  13. An J, Stadnicka A, Kwok WM,Bosnjak ZJ, Contribution of reactive oxygen species to isoflurane-induced sensitization of cardiac sarcolemmal adenosine triphosphate-sensitive potassium channel to pinacidil , Anesthesiology (2004); 100: pp. 575-80.
    Crossref | PubMed
  14. Bienengraeber MW,Weihrauch D, Kersten JR, et al., Cardioprotection by volatile anesthetics , Vascul Pharmacol. (2005); 42: pp. 243-52.
    Crossref | PubMed
  15. Chiari PC, Bienengraeber MW,Weihrauch D, et al., Role of endothelial nitric oxide synthase as a trigger and mediator of isoflurane-induced delayed preconditioning in rabbit myocardium , Anesthesiology (2005);103 : pp. 74-83.
    Crossref | PubMed
  16. Fujimoto K, Bosnjak ZJ, Kwok WM, Isoflurane-induced facilitation of the cardiac sarcolemmal K(ATP) channel , Anesthesiology (2002); 97: pp. 57-65.
    Crossref | PubMed
  17. Gassmayr S, Stadnicka A, Suzuki A, et al., Isoflurane sensitizes the cardiac sarcolemmal adenosine triphosphate-sensitive potassium channel to pinacidil , Anesthesiology (2003); 98: pp. 114-20.
    Crossref | PubMed
  18. Jamnicki-Abegg M, Weihrauch D, Pagel PS, et al., Isoflurane inhibits cardiac myocyte apoptosis during oxidative and inflammatory stress by activating Akt and enhancing Bcl-2 expression , Anesthesiology (2005); 103: pp. 1006-14.
    Crossref | PubMed
  19. Kehl F, Krolikowski JG, Mraovic B et al., Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction , Anesthesiology (2002); 96: pp. 183-8.
    Crossref | PubMed
  20. Kersten JR, Schmeling TJ, Hettrick DR et al., Mechanism of myocardial protection by isoflurane , Anesthesiology (1996); 85: pp. 794-807.
    Crossref | PubMed
  21. Kersten JR, Lowe D, Hettrick DA, et al., Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium , Anesth Analg. (1996); 83: pp. 27-33.
    Crossref | PubMed
  22. Kohro S, Hogan QH,Warltier DC, Bosnjak ZJ, Protein kinase C inhibitors produce mitochondrial flavoprotein oxidation in cardiac myocytes , Anesth Analg (2004); 99: pp. 1316-22.
    Crossref | PubMed
  23. Krolikowski JG, Weihrauch D, Bienengraeber M, et al., Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo , Can J Anaesth (2006); 53: pp. 174-82.
    Crossref | PubMed
  24. Kwok WM, Martinelli AT, Fujimoto K, et al., Differential modulation of the cardiac adenosine triphosphate-sensitive potassium channel by isoflurane and halothane , Anesthesiology (2002); 97: pp. 50-56.
    Crossref | PubMed
  25. Ludwig LM,Weihrauch D, Kersten JR, et al., Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species , Anesthesiology (2004); 100: pp. 532-9.
    Crossref | PubMed
  26. Nakae Y, Kwok WM, Bosnjak Z, Jiang MT, Isoflurane activates rat mitochondrial ATP-sensitive K+ channels reconstituted in lipid bilayers , Am J Physiol Heart Circ Physiol (2003); 284.
    Crossref | PubMed
  27. Novalija E, Kevin LG, Camara AK, et al., Reactive oxygen species precede the epsilon isoform of protein kinase C in the anaesthetic preconditioning signaling cascade , Anesthesiology (2003); 99: pp. 421-8.
    Crossref | PubMed
  28. Pagel PS,Warltier DC, Kersten JR, Effectiveness of Isoflurane in Inducing Delayed Preconditioning against Myocardial Infarction In Vivo , Anesthesiology (2006); 104: pp. 384-5.
    Crossref | PubMed
  29. Riess ML, Stowe DF,Warltier DC, Cardiac pharmacological preconditioning with volatile anaesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol (2004); 286.
    Crossref | PubMed
  30. Schlack W, Preckel B, Stunneck D,Thamer V, Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart , Br J Anaesth (1998); 81: pp. 913-19.
    Crossref | PubMed
  31. Stadnicka A,Bosnjak ZJ, Isoflurane decreases ATP sensitivity of guinea pig cardiac sarcolemmal KATP channel at reduced intracellular pH , Anesthesiology (2003); 98: pp. 396-403.
    Crossref | PubMed
  32. Stadnicka A, Kwok WM,Warltier DC, Bosnjak ZJ, Protein tyrosine kinase-dependent modulation of isoflurane effects on cardiac sarcolemmal K(ATP) channel , Anesthesiology (2002); 97: pp. 1198-1208.
    Crossref | PubMed
  33. Stadnicka A, Bosnjak ZJ, Kampine JP, Modulation of cardiac inward rectifier K+ current by halothane and isoflurane , Anesth Analg (2000); 90: pp. 824-33.
    Crossref | PubMed
  34. Stadnicka A, Bosnjak ZJ, Kampine JP, Kwok WM, Effects of sevoflurane on inward rectifier K+ current in guinea pig ventricular cardiomyocytes , Am J Physiol (1997); 273: pp. H324-32.
    PubMed
  35. Tanaka K, Ludwig LM, Kersten JR, et al., Mechanisms of cardioprotection by volatile anesthetics , Anesthesiology (2004); 100: pp. 707-21.
    Crossref | PubMed
  36. Toller WG, Gross ER, Kersten JR, et al., Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels , Anesthesiology (2000); 92 : pp. 1731-9.
    Crossref | PubMed
  37. Tonkovic-Capin M, Gross GJ, Bosnjak ZJ, et al., Delayed cardioprotection by isoflurane: role of K(ATP) channels , Am J Physiol Heart Circ Physiol (2002); 283.
    Crossref | PubMed
  38. Turner LA, Fujimoto K, Suzuki A, et al., The interaction of isoflurane and protein kinase C-activators on sarcolemmal KATP channels , Anesth Analg (2005); 100: pp. 1680-86.
    Crossref | PubMed
  39. Marinovic J, Bosnjak ZJ, Stadnicka A, Preconditioning by isoflurane induces lasting sensitization of the cardiac sarcolemmal adenosine triphosphate-sensitive potassium channel by a protein kinase C-delta-mediated mechanism , Anesthesiology (2005); 103: pp. 540-47.
    Crossref | PubMed
  40. Tsutsumi YM, Patel HH, Lai NC, et al., Isoflurane produces sustained cardiac protection after ischemia-reperfusion injury in mice , Anesthesiology (2006); 104: pp. 495-502.
    Crossref | PubMed
  41. Rainbow RD, Lodwick D, Hudman D, et al., SUR2A C-terminal fragments reduce KATP currents and ischaemic tolerance of rat cardiac myocytes , J Physiol (2004); 557: pp. 785-94.
    Crossref | PubMed
  42. Suzuki M, Sasaki N, Miki T, et al., Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice J Clin Invest (2002); 109: pp. 509-16.
    Crossref | PubMed
  43. Aizawa K,Turner LA,Weihrauch D, et al., Protein kinase C-epsilon primes the cardiac sarcolemmal adenosine triphosphatesensitive potassium channel to modulation by isoflurane , Anesthesiology (2004); 101: pp. 381-9.
    Crossref | PubMed
  44. Stadnicka A, Marinovic J, Bienengraeber M, Bosnjak ZJ, Impact of in vivo preconditioning by isoflurane on adenosine triphosphate-sensitive potassium channels in the rat heart: Lasting modulation of nucleotide sensitivity during early memory period , Anaesthesiology (2006); 104: pp. 503-10.
    Crossref | PubMed
  45. Garlid KD, Paucek P,Yarov-Yarovoy V et al., Cardioprotective effects of diazoxide and its interaction with mitochondrial ATPsensitive K+ channels , Circ Res (1997); 81: pp. 1072-82.
    Crossref | PubMed
  46. Pomerantz BJ, Selective mitochandrial adenosine triphosphate-sensitive potassium channel activation is sufficient to precondition human myocardium J Thorac Cardiovasc Surg (2000); 120: pp. 387-92.
    Crossref | PubMed
  47. Sato T, Sasaki N, Seharaseyon J et al., Selective pharmacological agents implicate mitochondrial but not sarcolemmal KATP channels in ischemic cardioprotection , Circulation (2000); 101: pp. 2418-23.
    Crossref | PubMed
  48. Terzic A,Dzeja PP, Holmuhamedov EL, Mitochondrial KATP channels: Probing molecular identify and pharmacology , J Mol Cell Cardiol (2000); 32: pp. 1911-15.
    Crossref | PubMed
  49. Nakae Y, Kohro S, Hogan QH, Bosnjak ZJ, Intracellular mechanism of mitochondrial adenosine triphosphate-sensitive potassium channel activation with isoflurane , Anesth Analg (2003); 97: pp. 1025-32.
    Crossref | PubMed
  50. Kohro S, Hogan QH, Nakae Y et al., Repeated or prolonged isoflurane exposure reduces mitochondrial oxidizing effects , Anesthesiology (2003); 98: pp. 275-8.
    Crossref | PubMed
  51. Jiang MT, Ljubkovic M, Nakae Y, et al., Characterization of human cardiac mitochondrial ATP-sensitive potassium channel and its regulation by phorbol ester in vitro , Am J Physiol Heart Circ Physiol (2006) ; In press.
  52. Kersten JR, Orth KG, Pagel PS et al., Role of adenosine in isoflurane-induced cardioprotection , Anesthesiology (1997); 86: pp. 1128-39.
    Crossref | PubMed
  53. Cope DK, Impastato WK, Cohen MV, Downey JM, Volatile anaesthetics protect the ischemic rabbit myocardium from infarction , Anesthesiology (1997); 86: pp. 699-709.
    Crossref | PubMed
  54. Tanaka K,Weihrauch D, Ludwig LM, et al., Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species , Anesthesiology (2003); 98: pp. 935-43.
    Crossref | PubMed
  55. Ito H,Vereecke J, Carmeliet E, Mode of regulation by G protein of the ATP-sensitive K+ channel in guinea-pig ventricular cell membrane , J Physiol (1994); 478: pp. 101-7.
    Crossref | PubMed
  56. Fish FA, Prakash C, Roden DM, Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators , Circulation (1990); 82: pp. 1362-9.
    Crossref | PubMed
  57. D'Alonzo AJ, Hess TA, Darbenzio RB, Sewter JC, Effects of intracoronary glyburide on cesium-induced arrhythmias in anesthetized dogs , J Cardiovasc Pharmacol (1994); 23: pp. 446-52.
    Crossref | PubMed
  58. Pasnani JS, Ferrier GR, Differential effects of glyburide on premature beats and ventricular tachycardia in an isolated tissue model of ischemia and reperfusion , J Pharmacol Exp Ther (1992); 262: pp. 1076-84.
    PubMed
  59. Lathrop DA, Contney SJ, Bosnjak Z, Stowe DF, Reversal of hypothermia-induced action potential lengthening by the KATP channel agonist bimakalim in isolated guinea pig ventricular muscle , Gen Pharmacol (1998); 31: pp. 125-31.
    Crossref | PubMed